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PERSPECTIVES AND SUMMARY
Scientists attempting to establish the molecular basis of neoplasia have repeat edly encountered the m�mbers of a small gene family known as ras. This acronym is derived from the words rat sarcoma because these genes were first identified as the transforming principle of the Harvey and Kirsten strains of rat sarcoma viruses (I, 2), two acute transforming retroviruses generated by transduction of the rat H-ras-l and K-ras-2 cellular genes, respectively (3, 4) .
The H-ras-I locus has been transduced into retroviruses on at least two additional occasions during the generation of the Rasheed strain of rat sarco ma virus (5) and the BALB strain of mouse sarcoma virus (6) . ras genes were inadvertently "rediscovered" when scientists, using gene transfer assays, established the existence of dominant oncogenes in human (7) (8) (9) (10) and carcin ogen-induced animal tumors (11) (12) (13) (14) . Most of these transforming genes have been identified as mutated alleles of cellular ras genes (11) (12) (13) (14) (15) (16) (17) (18) . More recent ly, ras oncogenes have been found in tumors induced by retroviruses that lack oncogene sequences. These viruses can integrate in the vicinity of cellular proto-oncogenes, disrupting their normal regulatory elements (19) . Activation of ras genes by retroviral insertional mutagenesis has recently been described in tumors of avian and mammalian origin (20, 21 ; J. Ihle, personal com munication) .
ras genes have been the focus of intense research since 1982 when their transforming alleles were first identified in human tumors. Unveiling the role of ras oncogenes in neoplastic development should have a major impact on our understanding of the pathogenesis of human cancer. However, research on ras genes is justified on its own merits. ras genes are likely to play a fundamental role in basic cellular functions based on their high degree of conservation throughout eukaryotic evolution. Independently of their phylogenetic origin, they code for proteins that bind guanine nucleotides (22) (23) (24) (25) , have GTPase activity (25) (26) (27) (28) (29) and arc associated with the plasma membrane (30) (31) (32) . These properties, along with their significant sequence homology with G proteins (33) (34) (35) (36) , suggest that ras proteins may participate in the transduction of signals across the cellular membrane.
Evolution has preserved their basic biological functions. ras proteins of yeast can transform mammalian cells (37) and mammalian ras proteins can support the growth of mutant yeast cells (37, 38) . Yet, ras proteins appear to participate in multiple, often distinct, biological processes. In mammals, they have been implicated in cellular proliferation (39) and terminal differentiation (40--42) . In yeast, they can be required for survival (43, 44) or mating (45) . Therefore , it is likely that ras proteins may function at a critical crossroads of signal transduction pathways. The study of ras genes and their oncogenic alleles is certainly a most fascinating field that has attracted scientists in terested in disciplines as diverse as yeast sporulation, control of cell prolifera tion, neural differentiation, carcinogen-DNA interactions, and human cancer.
During the last couple of years, reviews dealing with the structure and biochemical properties of ras proteins (46) and with the involvement of ras genes in hUlman cancer (47) (48) (49) and in carcinogen-induced tumors (50) have been published. In this review, I have compiled current information on the different arl eas of ras gene research in an attempt to convey an overall view of the fu ndamental role that ras genes play in normal and neoplastic cellular processes.
PRIMARY STRUCTURE
ras genes are an ubiquitous eukaryotic gene family. They have been identified in mammals, birds , insects, mollusks, plants , fu ngi, and yeasts. Sequence analysis of these genes and their products has revealed a high degree of conservation, which suggests that they may play a fu ndamental role in cellular proliferation. In this section, I present an overview of the most significant structural features of this gene family.
Mammalian ras Genes
To date, three ras genes have been identified in the mammalian genome (3, 4, 15-17, 51, 52). They have been designated H-ras-l, K-ras-2, and N-ras. Two pseudogenes, H-ras-2 and K-ras-l, have been identified and character ized in rats and humans (3, 4, 53, 54) and are likely to exist in most, if not all, mammals. Several mouse and hamster subspecies possess additional ras pseudogenes , probably due to a relatively recent germ line amplification (55) . Each of the three functional ras genes has been cloned and sequenced in at least two mammalian species. They include human H-ras-l (l0, 56--59), K-ras-2 (54, 60, 61) , and N-ras (5 1, 52, 62, 63) ; rat H-ras-l (3, 12, 64) and K-ras-2 (exons I and II only) (65) ; and mouse K-ras-2 (66) and N-ras genes (67 , 68) . Their location in both human and rodent chromosomes has also been determined (reviewed in 69). N-ras has been assigned to the short arm of human chromosome 1 (lp22-p32), whereas H-ras-l and K-ras-2 have been assigned to the short arms of chromosomes 11 (11pI5.1-pI5. 5 ) and 12 (12pI2. 1 -pter) , respectively. The chromosomal location of the two human ras psuedogenes (H-ras-2 maps in the X chromosome and K-ras-l in 6p12-p23) is also known. In the mouse, H-ras-1 has been mapped in chromosome 7, whereas K-ras-2 and N-ras have been assigned to chromosomes 6 and 3, respectively. Finally, in rats , the H-ras-1 gene has been mapped in chromo some 1, K-ras-2 in chromosome 4, and the H-ras-2 pseudogene in the X chromosome (70) .
The three functional ras genes code for highly related proteins generically known as p2 1 (7 1). The p21 coding sequences of each of these genes are equally distributed in four exons except for the K-ras-2 gene, which possesses two alternative fourth coding exons (exons IVA and IVB) that allow the synthesis of two isomorphic p2 1 proteins of 188 and 189 residues that differ in their carboxy terminal domains (54, 60, 72) . Although the spliced junctions of all mammalian ras genes correspond precisely, suggesting a common origin from one ancestral gene, their intron structures vary greatly. As a consequence, ras genes exhibit distinct genetic complexities ranging from the 4.5 kbp size of H-ras-l to the 50 kbp of K-ras-2. Mammalian ras genes contain an additional 5' noncoding exon (54, 60, 61, 73) located immediately downstream from their respective promoters (74, 74a) . These promoters do not possess the characteristic TAT A and CAT boxes commonly found in other eukaryotic genes. Instead, they are rich in G/C boxes, which are presumably involved in the binding of Spl proteins, a characteristic of the promoters of housekeeping genes (75) .
Comparison of the deduced amino acid sequences of mammalian H-ras-l, K-ras-2, and N-ras p21 proteins has helped to define four domains within these molecules (Figure lA ) . The first domain encompasses the amino ter minal third of p21 proteins and is a highly conserved region. For instance, the first 85 amino acid residues of mammalian p2 1 ras proteins of known sequence (human H-ras-l, K-ras-2, and N-ras, rat H-ras-2, and mouse K-ras-2 and N-ras genes) are identical ( Figure lA) . The next 80 amino acid residues define a second domain where the structures of the different mamma lian p21 ras proteins diverge slightly from each other (85% homology be tween any pair of human ras genes) . A highly variable region encompasses the rest of the molecule except for the last four amino acids, where the sequence CysI86-A-A-X-COOH (where A is any aliphatic amino acid) is present in all members of the ras gene family (Figure lA) .
ras Genes of Other Eukaryotes
ras genes have been highly conserved during evolution (76) . They have been identified in chickens (H-ras gene) (20) , fruit flies (Drosophila melanogaster Drasl, Dras2/64B and Dras3 genes) (77) (78) (79) , mollusks (A plysia Apl-ras gene) (80) , slime molds (Dictyostelium di scoideum Ddras gene) (81) pombe SPRAS gene) (82) (83) (84) . Comparative analysis of the deduced amino acid sequence of the products of these ras genes with mammalian p2l ras proteins shows a high degree of homology and the same structural domains ( Figure I ). Although some of the ras gene products of invertebrate species have additional amino terminal residues, they are at least 84% homologous to the highly conserved amino terminal domain of mammalian p2 1 ras proteins. This homology decreases substantially in the second, less conserved domain, and completely disappears in the variable carboxy terminal region with the exception of the conserved carboxy terminal Cys-A-A-X-COOH sequence.
The most striking property of the evolutionary conservation of ras genes is their ability to function in heterologous systems. Mammalian ras genes under the appropriate control of yeast promoters can complement nonviable rasl-ras2-yeast mutants (37, 38) . Moreover, mammalian ras oncogenes can induce phenotypic alterations in yeast cells (66, 85 ,) . Similarly, chimeric yeast-mammalian ras genes and a yeast RAS gene that carries a deletion in its long hypervariable domain are able to efficiently transform mouse NIH3T3 cells in gene transfer assays (37) . These results represent the fi rst report of interchangeability between functional genes of yeast and mammals and are the best example to illustrate the high degree of conservation of ras genes during evolution.
ras Oncogenes
Mammalian ras genes acquire transformation-inducing properties by single point mutatitons within their coding sequences (86) (87) (88) . Mutations in naturally occurring ras oncogenes have been localized in codons 12 (86-88), 13 (89), 59 (90, 91) , and 61 (62 , 63 , 92 , 92a) . In vitro mutagenesis studies have shown that mutations in codons 63 (93) , 116 (94) , and 119 (95) can also confer transforming properties to ras genes . Missense mutations in the corre sponding c()dons of the ras genes of S. cerevisiae also induce pronounced phenotypic changes that will be discussed in the section on yeast RAS genes.
The pres{�nce of a glycine residue at position 12 appears to be necessary for the normal :function of ras proteins. Substitution of Gly '2 by any other amino acid residue (with the exception of proline) results in the oncogenic activation of these molecules (96) . A similar affect is observed if Gly l2 is deleted or if additional amino acids are inserted between Ala " and Gly '2 (97). Substitu tion of the neighboring amino acid, Gly 13 , also has transforming con sequences for the harboring cells, although in this case not all substitutions appear to have the same activating effect (89, 93) . Whereas Val '3 and Asp '3 substitutions clearly yield ras oncogenes, replacement of Gly 13 by Ser l3 has little effect on the transforming activity of ras proteins (93) . Miscoding mutations in the domain surrounding codon 61 also play a very important role in the generation of ras oncogenes (62, 63 , 92 
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Schematic representation of the structural and functional domains defined within mammalian p21 ras proteins. (90, 91) or in vitro mutagenized ras oncogenes (93) . In all cases, substitution of the normal Ala59 by Th�9 has been observed. The effect of these mutations on the structure and biochemical properties of ras proteins will be discussed in the following section. Whereas all cellular ras oncogenes carry a single activating mutation, each of the four known retroviral ras oncogenes exhibits two mutations. The ras oncogenes of the Harvey and Kirsten strains have replaced both Glyl2 and Ala59 residues by Argl2 and Thr59 or Serl2 and Thr59, respectively (90, 91) .
The BALB strain exhibits two G � A transitions in codon 12, leading to a Gly 12 (GGA) � Lys 12 (AAA) substitution (99) . Finally, the ras gene product of the Rasheed strain, p29 ras, carries a Glyl2 � Argl2 substitution as well as 59 additional amino terminal residues derived from the helper virus gag gene piS protein (5) . The biological significance of these double mutations is not clear. It could be argued that they reflect selection of those viruses with more malignant properties. However, ras oncogenes carrying mutations in codons 12 and 59 are no more transforming than those carrying either mutation alone (93) . Moreover, in vitro studies have shown that substitution of Glyl2 by Lysl2 (as seen in BALB-MSV) generates a weakly transforming ras oncogene (96). Therefore, it is possible that the observed secondary mutations in retroviral ras oncogenes may be an evolutionary safeguard against excessive transforming properties.
ras-Related Genes
Emerging evidence suggests that ras genes are members of a super gene family. Genes exhibiting limited sequence homology to the ras gene family have been identified in a variety of eukaryotic organisms. For instance, a new class of genes, designated rho, code for proteins that share 30-40% homology with ras p2! proteins (100). rho genes have been identified in a variety of species, including such highly diverged organisms as snails (Aplysia) and humans. The human and Aplysia rho genes share 85% sequence homology, indicating that they are as well conserved in the phylogenetic scale as the ras genes (100). At least four additional ras-related genes that share 35-55% sequence homology with the ras gene family have been identified in humans and rodents (R-ras) (100a) primates (ral) (IOOb), fruit flies (Oras3) (79) , and yeast (YP2) (101) . The YP2 yeast gene has been recently shown to be involved in microtubule organization (lOla). Whether any of these genes are members of evolutionarily conserved gene families remains to be determined. Finally, some of these ras-related genes share significant sequence homology with at least one of the two domains (codons 12-13 and 59-61) frequently involved in the malignant activation of ras oncogenes. Whether any of these Annu. Rev ras-related genes can become oncogenes, either in vivo or by in vitro manipu lation, rem: ains to be determined.
BIOCHEMICAL PROPERTIES
ras proteins, independently of their phylogenetic origin, have been shown to bind guanine nucleotides (GTP and GDP) (22) (23) (24) (25) and possess intrinsic GTPase activity (25) (26) (27) (28) (29) . The relevance of these activities to the biological function of ras proteins has been demonstrated by three independent lines of evidence: (a) microinjection of anti-ras antibodies that inhibit gu anine nuc leotide binding (102) reverses the malignant phenotype of NIH3T3 cells transformed by ras oncogenes (103); (b) ras mutants that have lost their ability to bind guanine nUcleotides do not transform NIH3T3 cells (104, 105) ; and (c) the: GTPase activity of ras genes is severely impaired in their transforming alleles (25) (26) (27) (28) (29) . In addition to GTP/GDP binding and GTPase activity, ras proteins carrying an Ala59 -Th�9 mutation exhibit an auto phosphorylating activity of an, as yet, unknown biological significance (23) . In all cases, T�9 has been found to be the phosphate receptor site (106) . No transphosphorylating activity has been detected with any ras protein, includ ing those carrying T�9 mutations. The biochemical properties of ras proteins closely resemble those of the G proteins involved in the modulation of signal transduction through transmem brane signaling systems (107) . In fact, certain domains of ras proteins exhibit significant s, equence homology with the a subunit of G proteins such as G S ! a protein that activates adenylate cyclase in response to f3 adrenergic stimuli; Gio which inhibits this enzyme and perhaps activates phospholipase C; Go, a protein of as yet unknown function; and transducin, a protein that regulates cGMP phosphodiesterase activity in visual signal transduction (33) (34) (35) (36) . In addition to G proteins, other nucleotide-binding proteins such as the bacterial elongation factor Tu (EF-Tu), the f3 subunit of ATP-synthase, adenylateki nase, phosphofructokinase, and tubulin also exhibit certain sequence homolo gy to ras proteins (108-1 10).
In this section, the biochemical properties of ras proteins will be discussed in conjunction with genetic studies that have made it possible to assign certain functions to specific domains within these molecules .
Guanine Nucleotide Binding
The homology of ras genes with G proteins and EF-Tu is basically limited to regions encompassing amino acid residues 5-22 and 109-120 (108, 109) . Direct experimental evidence implicating these domains in guanine nucleotide binding has been obtained recently. Antibodies directed against epitopes located within the amino terminal region of ras proteins inhibit GTP binding by purified p2 1 ras proteins (102) . Conversely, the ability of these antibodies to bind to ras proteins is inhibited by preincubation with GTP or GDP (102). X-ray crystallography studies of the GDP binding domain of EF-Tu also support the concept that residues around codon 12 form part of the guanine nucleotide-binding site (109) . Based on EF-Tu and ras sequence homology, the 12th amino acid res idue (Gly) of mammalian ras proteins should be located in the phosphoryl binding loop (109, II I). Early studies have pre dicted that replacement of Gly '2 by any other amino ac id res idue (except proline) would disrupt the a-helical structure of the amino terminal domain of ras proteins, causing a conformational change that would prevent its proper folding (112) (113) (114) . Thus, replacement or elimination of Gly '2 may create a rigid domain that cannot efficiently interact with the phosphoryl region of the GTP molecule, reducing the GTPas e activity of ras proteins . Two additional residues in this domain, Gly l5 and Lys l6 , are present in other guanine nucleotide-binding proteins (109, III). Substitution of Lys 1 6 by Asn l6 signif icantly reduces GTP/GDP affinity without affect ing base specificity, an observation consistent with the idea that these residues are also part of the phosphoryl group (95) .
Crystallographic studies of the GDP' EF-T u complex predict that the guanine-binding pocket may interact with two noncontiguous segments of EF-T u that are present in ras proteins (Asn 1 1 6 -Lys_Cys_AspI1 9 and Ser 14 5_ Ala-Lys'47) (109, III). ras deletion mutants within residues 109-120 or 130--145 do not bind detectable levels of guanine nucleotides and cannot induce efficient transformation of NIH3T3 cells (104) . Moreover, two of three GTP-binding-defect ive ras mutants isolated by random mutagenesis (ASp "9 � Asn "9 and Thr l44 � lIe 144 ) map within these regions (115) . Direct biochemical evidence supporting the concept that these regions interact with the guanine ring has been obtained by introducing mutations in residues 116 and ll Y (Y4, 95). Substitution of normal Asn"6 by a variety of amino acids including isoleucine, lysine, tyrosine, and histidine decreases the bind ing of guanine nucleotides by several orders of magnitude to below detection levels (94, lISa, 115b). However, only a IO-fold decrease in binding was observed if asparagine was replaced by a related amino acid residue such as glutamine (94). These observations are consistent with the prediction from EF-Tu'GTP crystallographic studies that Asn ll6 may form a hydrogen bond with the 0 6 residue of guanine (116) . Substitution of Asp ",) by alanine leads to a 50-fold increase in the dissociation rate of guanine nucleotides (95) . In contrast , the Asp l19 � Ala l19 mutation has no effect on the dissociation rate of inosine diphosphate, a molecule identical to GDP except for the absence of the amino residue in position 2. These results suggest that Asp l 1 9 may form a hydrogen bond with the 2-NH2 group of guanine nucleotides (95 Figure I) . Substitution of Arg 164 by Ala 164 also results in loss of GTP binding activity (105) . Thc lack of homology between this domain and EF-Tu has madc it impossible 10 predict whether these res idues in general, or Arg l64 in particu lar, are part of the GDP binding site. Independent studies have shown that substitution of ras oncogene residues 164 to 174 by the sequence Pro-Asp-Gln does not result in loss of transforming activity (118). Thus, it is possible that the domain surrounding the conserved Arg l64 res idue plays an indirect role in the binding of guanine nucleotides .
The Effector Domain
Extensive work on deletion mutants of mammalian ras genes has led to the definition of five noncontiguous domains (residues 5-63 , 77-92, 109-123, 139-165, and the carboxyl terminal sequences Cys IX6 _A-A-X-COOH) that are absoluteJy required for ras function (104). Whereas some of these do mains have been clearly implicated in guanine nucleotide hinding, others might play a role in effector recognition. Amino acid substitutions at positions 35 (Thr --,> Ala), 36 (lIe � Ala), 38 (Asp � Ala), and 40 (Tyr --,> Lys) have been shown to reduce the biological effect of ras proteins in assays utilizing both mammalian (NIH3T3 fo cus fo rmation) and yeast (complementation of growth of RASlras2 mutants on non fe rmentable carbon sources and stimula tion of adenylate cyclase) cells (119) . These mutations do not disrupt the known biochemical activities of these molecules, suggesting that res idues 35--40 might be implicated in the effector activity of ras proteins (119). Additional support for this hypothesis comes from the observation that all indispensable domains of ras proteins lie in internal hydrophic regions except for the domain corresponding to residues 30 to 42, which is hydrophilic and presumably located in the external surface of the molecule (104). These findings suggest that this domain may be involved in the interaction of ras proteins with their putative cellular targets ( Figure 1B) . Recently, a Gln4 3 � Arg4 3 substitution has been found to be responsible for the temperature sensitive phenotype of the 371 strain of . Although the structural consequences of this mutation have not been established, these results add fu rther evidence to the importance of this domain for proper ras protein function.
Neutralizing Antibodies
One of the reagents most commonly used to characterize ras proteins is a rat monoclonal antibody designated Y13-259 (120) . This antibody must bind to a highly conserved domain of ras proteins as deduced by its ability to recognize the products of each of the mammalian ras genes (62, 120) as well as the ras proteins of invertebrate species (24, 12 1, 122). More importantly, this anti body has been recently shown to specifically block the serum-induced mitogenic response of certain cells in culture and to inhibit morphologic transformation induced by mutated ras proteins (39, 123) . Binding studies utilizing the products of ras deletion mutants have localized the epitope recognized by this antibody within residues 70-89 (124) (Figure 1B ). More refined analysis has established that the Y13-259 antibody interacts with the side chains of residues Glu63, Ser65, A1a66, Met67, G1n7o, and Arg7 3 (119). Substitution of any of these residues completely abolished the interaction of ras proteins with the Y13-259 antibody in immunoblotting assays. In con trast, substitution of residues 61, 62, 64, 68, 71, 72, 75, 78 , or any other residue outside the 60-80 region of ras proteins had no detectable effect on their affinity for the Y13-259 antibody (119).
Residues critical for Y13-2S9 binding are presumably located in the ex posed, hydrophilic site of an a helix that forms a structure about 20 A long, a distance consistent with the dimensions of an antibody-binding site (119) . Binding of Y13-259 to ras proteins does not affect any of their known biochemical properties (124) . Moreover, the Y13-259 antibody-binding do main lies in a dispensable hydrophilic region (104, 119) . Therefore, it is likely that the biological activities observed by binding of Y13-259 antibodies to ras proteins are exerted through indirect conformational changes.
Membrane Attachment
ras proteins have been localized in the inner side of the plasma membrane (30-32). The primary translational product of ras oncogenes is synthesized in Processe:d ras proteins attached to the plasma membrane exhibit a faster migration rate in SDS-polyacrylamide gel electrophoresis than their un modified c:ytosolic counterparts (32, 127, 128) . It was presumed that this change in mobility was the result of the acylation of the CyslS6 residue. However, it is likely that an as yet unidentified posttranslational modification may take place prior to fatty acid acylation. In yeast, RAS proteins are converted to forms with faster electrophoretic mobility before the attachment of palmitic acid (32). Studies with mammalian p2 1 ras proteins indicate that removal of lipids does not restore the mobility of the mature protein to that of the precursor form (127). Moreover, the products of ras deletion mutants with a slow ralte of acylation exhibit an altered electrophoretic mobility in dependently of whether they contain palmitate (membrane fraction) or not (cytosolic fraction), indicating that the change in electrophoretic migration is not a consequence of acylation (130) . Thus, it is likely that ras proteins may undergo two steps of posttranslational modification before they become attached to the plasma membrane.
Dispensable Domains
At least five noncontiguous domains of ras proteins have been shown to be dispensable for their biological function. They include the amino terminal end, three internal domains, and the hypervariable region. Evidence that the first few amino acid residues are not important for ras function comes from the variability in both the type and number of residues found in this region in the different ras gene products ( Figure IA) . Moreover, H-ras p21 proteins in which the first three amino acids were replaced by unrelated residues retained their biological properties (131).
In vitro mutagenesis studies utilizing viral ras oncogene DNA clones have indicated that three internal domains (residues 64-76, 93-\08, and 124-138 in mammalian proteins) can be deleted without drastically affecting their transforming properties (\04) . Each of these domains corresponds to hydrophilic: regions that are presumed to be located in the external surface of ras proteins (104). It is possible that they represent long hinge regions that can be deleted without serious consequences to the overall structure of the mole cule. However, in vitro mutagenesis studies must be performed with ras oncogenes whose products do not require external signals for activation. Therefore, it is conceivable that a putative receptor domain might be found to Annu. Rev be dispensable in these assays. Whether any of these domains are involved in receptor signaling remains to be determined. Deletion of the entire hypervariable region (residues 166-185 in mamma lian ras proteins, see Figure I ) does not affect any of the known hiochemical properties of ras proteins nor their ability to transform NIH3T3 cells (105, 118) . It is likely that this long stretch of amino acids, which has been maintained throughout evolution, plays an important role in ras function. It is possible that ras proteins utilize this domain to interact with other proteins. Its intrinsic variability may serve to confer different functional properties to each of the members of this gene family. Development of biological assays for ras proteins other than cellular transformation (e.g. complementation of S. cere visiae ras-mutants) might shed light on whether these apparently dispensable domains play any role in the biological function of ras proteins.
A Model fo r the Function of ras Proteins
The biochemical and biological properties of ras proteins, along with their strong resemblance to G proteins, have led to the proposal that ras proteins may be involved in signal transduction. A schematic diagram of the currently favored model is shown in Figure 2 . This model proposes that ras proteins exist in equilibrium between an active and an inactive state. Most of the ras molecules in a given cell would exist in their inactive state, which is charac terized by a conformation that allows binding of GDP. Normal ras proteins will remain in their inactive state until they receive a stimulus from another protein (a receptor?) upstream of a putative pathway of signal transduction. This stimulus' would result in the exchange of GDP for GTP followed by a conformational change of the ras protein to its active state. Active ras proteins would then be able to interact with their putative effector molecules.
Once the interaction between the active ras proteins and the effector has taken place, they would be immediately deactivated. This can be accomplished by their intrinsic GTPase activity, which would catalyze the hydrolysis of GTP returning the active ras protein to the inactive GDP-bound state ( Figure 2) . This model takes into account that mutations known to confer transforming properties to ras genes must reverse the normal equilibrium between the inactive and active forms. Stabilization of ras proteins in their active state would cause a continuous flow of signal transduction, which will result in malignant transformation ( Figure 2) . Theoretically, this process can be achieved by mutations that inhibit the intrinsic GTPase activity of ras proteins (Figure 2a 
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molecules in their GTP-bound active state to induce malignant transformation without affecting the equilibrium between inactive and active fo rms characteristic of normal ras proteins. Experimental evidence indicates that inhibition of their GTPase activity is the preferred mechanism of activation of oncogenic ras proteins (25) (26) (27) (28) (29) 117) . ras oncogenes carrying ASp l1 6 � lIe l 1 6 or ASp l19 � Asp" 9 substitutions may exert their transforming properties by mechanisms involving increased dissociation rates of the complex between guanine nuc Ieotides and ras proteins (94, 95) (Figure 2b) . Such an increase in the dissociatiolll rate would result in a significant reduction of the affinity of GOP and GTP for ras proteins. This would favor the fo rmation of the active [ras protein-GTP] complex due to the higher availability of GTP molecules in the cell. However, in the case of the transforming ras gene carrying the Asp 1 16 � lie 1 1 6 mutation, its gene product does not bind detectable levels of GTP (94) . Whereas this observation might be due to the unusually high dissociation rate (and therefore low affinity) of the [p21 ·GDP/GTP] complexes, it is conceiv able that substitution of aspartic acid by a hydrophobic residue such as isoleucine may induce a conformational change that can activate the ras p21 protein without participation of guanine nucleotide binding ( Figure 2c) .
A discrepancy appears to exist regarding the mechanism by which the Ala59 � Th�9 mutation activates ras oncogenes. Whereas some authors have reported that these mutants possess low GTPase activity (25, 26) , other investigators have found a normal GTPase (132) and increased GDP/GTP dissociation rates (132a). The reasons for these discrepancies remain to be determined.
ras PROTO-ONCOGENES: BIOLOGICAL PROPERTIES
Unveiling the cellular role of ras genes requires the use of model systems amenable to genetic analysis. (82, 83, 134) . Genetic analysis of the RASI and RAS2 genes of S. cerevisiae has established that neither of them are essential for the viability of these cells (43 , 44) . Cells containing disruptions in either of these genes can undergo both mitotic and meiotic cell division cycles. However, rasl-ras2-spores of doubly heterozygous diploids are not capable of vegetative growth (43, 44) . These findings clearly illustrate the importance of RAS genes for normal cellular proliferation.
Yeast RAS gene products exhibit the same biochemical properties as their mammalian counterparts. They bind GDP and GTP and have an intrinsic GTPase activity (24, 25) . RAS proteins carrying Ala66 � Thr66 (equivalent to mammalian position 59) and Gln68 � Leu68 (equivalent to mammalian position 61) mutations bind normal levels of guanine nucleotides but have an impaired GTPase activity (25) . Moreover, the Thr 66 mutant exhibited auto-phosphorylating activity (25) . These findings suggest that S. cerevisiae RAS proteins m:ay also function as G proteins according to the model depicted in Figure 2 .
Preliminary evidence indicates that S. cerevisiae RASI and RAS2 genes do not have the same cellular function. Extensive genetic analysis of the RAS2 locus indicates that this gene is necessary for a normal response to nutrient limitation. ras2-mutants, although viable, have a defect in gluconeogenic growth, accumulate excessive levels of storage carbohydrates, and sporulate prematurely (133, 135, 136) . In general, disruption of the RAS2 locus results in an overall premature starvation response. The multiple phenotypes observed in ras2-mutants may not necessarily be interconnected. For in stance, the inability of ras2-mutants to grow in media containing nonfermentable carbon sources appears to be a consequence of the decrease of RASI gem; expression under these culture conditions (137). Inhibition of RASI gene transcription coupled with the ras2-mutation may lead to a cell cycle arrest comparable to that observed in rasl-rasZ-mutants (43 , 44) .
Support for this hypothesis comes from the observation that suppressors of the ras2-defect in gluconeogenic growth led to a significant increase in RASI mRNA levels (137, 137a) . However, direct suppression of the ras2-phe notype in non fermentable carbon sources by chimeras capable of con stitutively expressing RAS I proteins remains to be demonstrated. In contrast, the RASI product does not seem to play any role in the hypersporulating properties of ras2-mutants, since the same suppressors that allow these cells to grow on non fermentable carbon sources have no effect on the hyperspomlation phenotype (137). Recent studies have suggested that RAS I may play an indirect role in the regulation of glucose-induced in ositolphospholipid turnover (137b). These observations indicate that the RAS genes of S. eerevisiae play different cellular roles in spite of their high sequence homology and genetic complementarity.
Detailed genetic analysis of the RAS2 locus has made it possible to identify the cellular pathways in which this gene is involved. Introduction of a Gly'9 � Val19 substitution (equivalent to mammalian 12 position) in RAS2 results in a dominant gene capable of inducing a series of phenotypic changes in yeast cells (43, 133) . RAS2 Val19 mutants exhibit a very low sporulating efficiency and can arrest at any phase of the cell cycle upon nutritional stress (43, 133) . It it worth noting that this phenotype is the opposite of that induced by elimination of the RAS2 gene (133) (134) (135) (136) , an observation consistent with the idea that mutations in the critical Gli9 codon lead to an enhancement of the normal properties of the RAS2 product. Comparison of the characteristic phenotype of RAS2 Val 19 mutants with other known yeast mutants has provided fundamental clues regarding the cellular function of the RAS2 gene (133) . It was observed that bey I , a suppressor of adenylate cyclase -deficient (eyr-) yeasts (138) , exhibited an almost identical phenotype to RAS2 Val19 cells. hey I is a recessive mutant that affects the regulatory subunit of the cAMP-dependent protein kinase (139) . As a consequence, bey I strains bypass this regulatory step and induce the constitutive activation of the catalytic subunit of this kinase. Genetic crosses between bey I and several ras mutant strains have conclusively demonstrated that bey I suppressed the lethality induced by the ras l -ras2-genotype (133). Similar results have recently been obtained with an extragenic suppressor mutant designated sra l (J37a), which is likely to be an allele of bey I. Other mutations that allow ras 1 -rasT cells to grow have been identified as alleles of adenylate cyclase that produce elevated levels of cAMP (137a, 139a). These observations indicate that RAS genes must play a role in the adenylate cyclase signal transduction pathway somewhere upstream from the step involved in the regulation of the cAMP dependent protein kinase activity. As indicated above, adenylate cyclase is regulated by G proteins whose biochemical properties closely resemble those of ras proteins (107 ). Thus, these studies have raised the interesting possibil ity that S. cerevisiae RAS genes may be regulatory G proteins that control adenylate cyclase.
Subsequent biochemical studies have supported these genetic observations.
S. cerevisiae cells carrying the dominant RAS2 Val l'! mutant exhibit a 4-fold increase in the levels of cAMP (140) . In contrast, RAS l ras2-and ras l-ras2-heyl strains have 4-and 20-fold lower levels of cAMP than wild-type cells, respectively (140) . The fact that ras 1-RAS2 strains only have slightly depressed cAMP levels adds further support to the concept that RASI and RAS2 genes play different cellular roles. In vitro studies utilizing purified RAS2 proteins and crude membrane extracts indicate that the increased levels of cAMP arc duc to stimulation of adcnylatc cyclase activity by RAS2 proteins (140) . This stimulation is dependent on the presence of guanine nucleotides, an expected finding considering the structural and functional homologies between RAS genes and regulatory G proteins. GTP was found to be 50% more efficient than GOP in the RAS2-dependent stimulation of cAMP synthe sis (140) . Moreover, a RAS2 Vall') protein that has a defective GTPase is about 2-fold more efficient than a wild-type RAS2 molecule in stimulating cAMP synthesis . However, if GTP is substituted by a nonhydrolyzable derivative, thus making this reaction independent of the presence of GTPase activity, wild-type RAS2 and RAS2 Val'9 mutant proteins exhibit the same high stimulatory effect (140) . Similar experiments were conducted in Escherichia coli cells transformed with S. cerevisiae adenylate cyclase (C YR I) and RAS2 genes (141) . Transfor mants containing the CYR I gene possess a GTP-independent adenylate cy clase activity, which becomes GTP-dependent upon transformation with the RAS2 expression plasmid. Substitution of RAS2 by RAS2 Val19 resulted in Annu. Rev both loss of the GTP dependency and increase in the amount of cAMP synthesis. Reconstitution of the GTP-dependent adenylate cyclase was observed by mixing membranes from CYRlras l-ras2-bcy l yeast with E.
coli cell extracts containing RAS2 proteins or by mixing membranes of cyr iRAS I RAS2bcy l yeast with E. coli extracts containing adenylate cyclase (14 1). These observations, taken together, indicate that the RAS2 gene of S.
cerevisiae participates in the control of adenylate cyclase. These studies, however, do not resolve whether RAS2 is the regulatory subunit of the catalytic domain of the yeast adenylate cyclase complex. Several lines of evidence argue against this straightforward hypothesis. For instance, yt:ast cyr-mutants are viable, whereas rasl-ras2-are not. There fore , RAS genes must be involved in additional pathways independent of adenylate cyclase. It is possible that the RAS2 protein activates adenylate cyclase by interacting with its regulatory subunit, forming a G protein cas cade. However, ras gcncs and adenylate cyclase are not linked functionally in other eukaryotic organisms. Mammalian epithelial and fibroblastic cell lines transformed with retroviral ras oncogenes exhibit reduced adenylate cyclase activity (142) . Moreover, purified p2 1 ras proteins do not activate adenylate cyclase in crude mammalian cell membranes (142) . Similarly, human ras proteins can induce maturation of frog (Xenopus) oocytes without affecting their cAMP levels (143). These observations argue against a direct interaction between RAS proteins and the regulatory and/or catalytic subunit of the adenylate cyclase enzymatic complex.
Among Ithose eukaryotic organisms in which ras genes do not seem to interact with adenylate cyclase is the fission yeast S. pombe. S. pombe possesses a single ras gene, designated SPRAS, which codes for a protein of 219 amino acids whose sequence also conforms to the four structural domains of other ras proteins (84) ( Figure IA) . The SPRAS protein plays a physiolog ical role completely different from those of S. cerevisiae RAS products (45, 143a) . Disruption of the SPRAS locus does not interfere with either growth rates or with the response to nutritional stress conditions. Instead , S. pombe spras-mutants completely lose their ability to mate (45, 143a) . In addition, these mutations repress rather than stimulate sporulation and they do not affect the intracellular levels of cAMP. So far, there is no genetic or biochem ical information regarding the pathways in which the SPRAS gene might be involved in S. pombe.
The lack of association between ras genes and adenylate cyclase in all the eukaryotic organisms studied so far except for the yeast S. cerevisiae represents an evolutionary puzzle. It is pussible that ras proteins function at a pivotal crossroads of signal transduction pathways. If so, selection of one pathway over another may have changed during evolution depending on the particular physiological necessities of each organism. In support of this view Annu. Rev is the observation that S. cerevisiae depends on its intracellular levels of cAMP to exit from G, into the S phase and to switch from G, into the sporulation pathway (144). In contrast, there is no evidence for the involve ment of cAMP in the control of the life cycle of S. pombe. Thus, if ras proteins were to be involved in the regulation of cell proliferation it is likely that in S. Cerevisiae they do so by interacting with adenylate cyclase.
However, other organisms in which cAMP does not play such a role in the control of cell growth may not require that their ras products interact with the adenyl ate cyclase pathway.
ras
Genes of Other Invertebrates
The function of ras genes has been investigated in several invertebrate organisms, including the slime mold D. discoideum. the fruit fly D.
melanogaster. and the mollusk Aplysia. The D. discoideum Odras gene was accidentally identified during the course of studies aimed at isolating genes differentially regulated during development (81). A 1.2 kbp Odras mRNA is expressed at high levels in vegetative cells and disappears at the beginning of differentiation. Two species of Odras mRNA (0.9 and 1. 2 kbp) appear again at the end of the aggregation period (about 12 hours), reaching a maximum after 15 hours, and disappear by 22. 5 hours, coinciding with midculmination (81). Protein studies indicate that p23, the Odras gene product, is also expressed at high levels during vegetative growth and decreases during development (82, 121 ) . Whereas some authors have reported that the decrease in p21 expression is a slow and steady process (82) , others have shown a remarkable decrease in the amount of p23 with the onset of differentiation followed by a rise during cellular pseudoplasmodial formation, finally de creasing to the lowest level during the late stages of differentiation (121). These latter results support the concept that Ddras p23 expression correlates with the rate of cell proliferation in D. discoideum. Transformation of D. discoideum cells with a series of antisense RNA Odras constructs linked to a neoR gene led to a low number of geneticin resistant survivors , none of which carry the antisense Ddras vectors (145). These results have been interpreted as evidence that ras genes are required for cellular proliferation. However, it is not known whether these antisense constructs had any effect on endogenous Odras expression. More recently, the effect of Glyl9 (equivalent to mammalian Gly'2) Odras mutants (Thr '9) have been shown to induce aberrant developmental phenotypes in this microorganism, suggesting an effect of ras genes on cAMP-mediated signal transduction (l45a). Unfortunately, none of the biochemical parameters in volved in the cAMP-mediated signal transduction pathway appear to be significantly affected by the Ddras-Thr '9 mutant (145a).
In D. melanogaster. molecularly cloned (77) (78) (79) . Dras-l and Dras2/64B are the loci most closely related to the human H-ras-l gene, in spite of some discrepancies in the sequence of the latter (77 , 78) . Dras3 , an intronless gene, is more distantly related, although chimeric human H-ras-l and Dras3 genes were able to transform NIH3T3 cells with low efficiency (79) . To date , no genetic studies have been reported suggesting that these loci are located in chromosomal regions not: easily accessible to genetic analysis. Each Dras locus appears to code for two or three transcripts of different sizes, which are constantly expressed throughout the development of the fly, although the shorter tran scripts appear to be more abundant during the early embryonic stages (78, 146) . In situ hybridization studies have shown that transcripts from each Dras gene exhibit similar distribution at every developmental stage (147) . Howev er, a correlation between Dras expression and cell proliferation has been observed. Whereas in embryos the Dras transcripts are uniformly distributed, in larvae till ey are restricted to the dividing cells (147) . This picture completely changes in the adult fly. Here, the highest levels of Dras RNA are found in fully differentiated, nondividing cells such as the ovaries and the cortex of brain and ganglia (147) . Similar results have been recently observed in the marine mollusk, Aplysia (80). In this organism, ras proteins afl� most abundantly expressed in nervous tissue, in the ovotestis, and in fertilized eggs. Immunocytochemical analysis of the nervous tissue re vealed that ras proteins are present in the neuronal cell bodies, as well as in the axons and in the neuropil (80) . These studies suggest that ras genes may play a role not only in cell proliferation but also in processes involving terminal cell differentiation. ras 
Genes of Mammalian Cells
The biological function of ras genes in mammalian cells is poorly understood. The existence of mutants (oncogenes) capable of inducing transformation specific phenotypes suggests that these genes may play a role in cell prolifera tion. However, ras oncogenes can induce terminal differentiation of PC 12 neural cells (40-42) (see p. 805). Thus , ras genes of mammals may also play a dual role in proliferation and in certain differentiation processes.
The difficulty of direct genetic manipulation of ras loci within mammalian cells has been partially overcome by microinjection studies using monoclonal antibodies directed against p21 ras proteins. Early studies have shown that micro in jection of purified mouse ras Lys 1 2, human ras V a1 1 2, or retroviral ras Arg12 Thr59 mutant p21 proteins into NIH3T3 mouse fibroblasts led to transient morphologic transformation and cell proliferati � n (148-150). Sim ilarly, anti -p2 1 monoclonal antibodies were able to induce transient reversion of the malignant phenotype of rodent cells transformed by ras oncogenes (103, 123) . These studies have been taken one step further by examining the effect of YI3-259, a monoclonal antibody capable of recognizing all known ras proteins (120), in NIH3T3 cells. Microinjection of this antibody into the cytoplasm of NIH3T3 cells prior to serum stimulation leads to a significant decrease in the number of cells capable of Jritiated thymidine uptake (39). These results indicate that cells injected in G" were blocked from entering the S phase. Time course experiments suggest that ras gene proteins arc not required once the cells have entered the S phase. Instead, they appear to be necessary at about eight hours after serum induction, a time that is estimated to coincide with the beginning of the S phase (39) . The validity of these observations has been confirmed by showing that NIH3T3 cells transformed by a ras mutant that cannot bind the Y 13-259 antibody are not prevented from entering the S phase (151). Studies utilizing antibodies specific for each of the mammalian ras products may provide additional information on the role of each of these proteins in the proliferation of mammalian cells.
The location of ras proteins in the inner surface of the cell membrane (30), along with their similarity to G proteins (107), has raised the possibility that ras proteins may participate in the transduction of mitogenic signals. The direct effect of ras proteins in the dynamics of cellular membranes has recently been investigated by microinjection experiments (151 a). Both normal and transforming ras p2 1 proteins induce the appearance of increased surface ruffles and fl uid-phase pinocytosis. Whereas the effect of the normal protein is short-lived, that of its transforming counterpart re mains for at least IS hr after injection (151 a). Increased ruffl ing and pinocytosis are also characteris tic membrane responses to certain hormones and mitogenic compounds. These observations support the view that ras proteins participate in signal pathways initiated at the cellular surface.
Identification of the receptor and effector systems that interact with ras proteins has, so far, been elusive. It has been reported that the GDP binding activity of ras proteins in rodent cells transformed by ras oncogenes is stimulated by the addition of epidermal growth factor (EGF) (152). These observations, along with the increased production of TGFa, an EGF-like growth factor, by ras-transformed cells, have suggested a certain degree of biochemical interaction between ras proteins and the EGF receptor pathway.
More recently, it has been suggested that ras genes may play a regulatory role in the phosphatidylinositol pathway. Rodent fibroblasts transformed by diffe rent ras oncogenes exhibit elevated steady-state levels (2-to 3-fo ld) of phosphatidylinositol-4,5-biphosphate (PIP2) and their breakdown products, the second messengers 1,2-diacylglycerol (DAG) and inositoI-I,4,5-triphosphate (lp}) (l52c). Similar re sults have been obtained when NIH3T3 cells carrying an inducible N-ras proto-oncogene were treated with several growth factors such as bombesin and bradykinin but not with EGF or PDGF (l52d). These observations have led to the proposal that N-ras p2 1 proteins may be identical to Gp, the putative G protein that mediates the activation of phospholipase C, the enzyme responsible for the breakdown of PIP2 into DAG and IP3 (152d). However, in related experiments in which ras p2 l proteins were microinjected into REF52 rat fibroblasts, stimulation of phos pholipase A2 was observed instead (15la). Additional experiments are needed to determine whether these observations have physiological relevance or are merely due to an overflow effect caused by the high levels of ras proteins present in these cells.
Studies . on the effect of Y13-259 antibodies on the proliferative properties of NIH3T3 cells have provided some additional clues. Cells transformed by oncogenes whose normal alleles have been identified as growth factor recep tors (fms) or that are known to interact with the plasma membrane lfe s and src) cannot enter the S phase if microinjected with Y13-259 antibodies (153). In contrast, this antibody has no effect on cells transformed by two oncogenes whose products are known to be located in the cytoplasm (mas and raJ) . These results have been interpreted as evidence that ras genes are involved in signal transduction from a variety of receptors and other membrane-associated molecules (153) . However, other interpretations are also possible. Further studies with additional oncogenes as well as with antibodies directed against other proto-oncogenes and membrane proteins such as growth factor recep tors, protein kinase C, phospholipases, etc , will be necessary to assess the usefulness of this experimental approach.
Studies on the expression of ras genes in mammalian cells indicate that they are expressed at low levels in most, if not all, cell lineages. Unlike other proto-oncogenes, ras genes are consistently expressed throughout develop ment of the mouse embryo (154, 155) . Increased expression (up to eightfold) of ras genes has been reported in actively proliferating tissues such as regenerating rat liver (156) . However, increased levels of ras expression do not always correlate with cellular proliferation . Studies aimed at determining the levels of ras proteins in different rat organs have found the highest p21 ras expression levels in brain, whereas proliferating tissues only show limited expression (157) . A similar study in the mouse revealed the highest levels of expression in heart, another nondividing tissue (158).
More recently, an extensive immunohistochemical survey of p21 ras ex pression in normal fetal and adult human tissue has been conducted (M. Furth , C. Cordon-Cardo, personal communication) . In each case, im munoblots of tissue lysates were used to corroborate the immunohistochemi cal data. The basic conclusions from these studies are (a) almost every fetal and adult tissue expresses detectable levels of p2 1 proteins; (b) in most cell lineages, the level of p21 expression was significantly higher in immature than in diffe rentiated cells; and (c) certain terminally differentiated cells, including epithelial cells of endocrine glands and the neurons of the central nervous system, expressed high levels of p2 1 proteins. These findings add fu rther support to the concept that ras genes play a dual role in basic cellular proliferation and in certain specific functions of terminally di fferentiated cells. ras 
ONCOGENES

Mechanisms of Activation
ras genes can acquire transforming properties by qualitative and quantitative mechanisms. As indicated throughout this review, missense mutations within certain domains yield highly efficient transforming ras genes. However, increased expression of normal ras proto-oncogenes can also induce certain manifestations of the malignant phenotype. Linkage of normal ras genes to retroviral regulatory elements (L TR) results in the malignant transformation of NIH3T3 cells (3, 159, 159a) . Similar results have been obtained by integration of multiple copies of a DNA clone of the normal human H-ras-1 gene (160). These tumorigenic cells invariably show 30-to 100-fold higher levels of ras gene expression than either their normal counterparts or cells transformed by ras oncogenes activated by single point mutations (159, 159a, 160) . In general terms, the neoplastic properties induced by highly over expressed ras proto-oncogenes are more limited than those induced by their mutated alleles even when driven by their own promoters. Combination of qualitative and quantitative alterations of ras genes results in oncogenes (e.g. retroviral ras oncogenes) capable of inducing a more complete spectrum of neoplastic pheonotypes.
In vitro Transforming Properties
Cellular ras oncogenes transform established rodent cell lines in a dominant fashion (47) (48) (49) . Neither the resident proto-oncogenes nor cotransfection with their respective normal alleles affects the transformation efficiencies of ras oncogenes. However, their levels of expression appear to modulate their transforming potency (161) . ras oncogenes are necessary not only for initia tion, but also for maintenance of the transformed phenotype. This has been demonstrated by the existence of a Kirsten-MSV ts mutant (162) and by in vitro experiments in which ras oncogenes were linked to inducible promoters (163) or used to induce reversible transformation of normal rat fibroblasts (161) .
Cellular ras oncogenes cannot transform rat primary embryo cells (164) (165) (166) . Tranformation of these cells by ras oncogenes requires the cooperation of nuclear oncogenes (167) such as c-myc (164), adenovirus E1A (165), polyoma large T (164) , N-myc (168) , or p53 (169, 170) . Alternatively, ras oncogenes can transform rat embryo cells if the surrounding cells are elimin-ated, for instance, by cotransfection with the neo gene followed by selection with genelticin (171-173) . Linkage of ras oncogenes to transcriptional enhancers increases the percentage of cells that become transformed under these experimental conditions (171) .
The molecular basis for the inhibitory effect of the surrounding cells remains to be elucidated. Reconstitution experiments indicate that normal cells can inhibit the transformed phenotype of ras-transfected cells only if plated at high cell density (174) . These results explain early observations indicating that ras-containing retroviruses can transform rat primary embryo cultures (175) but only at high multiplicity of infection (L. Parada, personal communication). This inhibitory effect can be partially overcome by treating the ras-containing primary embryo cells with tumor promoters such as 12-0-tetradecanoyl-phorbol-13-acetate (TPA) (172). However, most TPA-treated or geneticin-resistant rat embryo cells carrying ras oncogenes alone will only divide a fe:w times and will not become established as cell lines (172, 173) . Quantitative experiments have indicated that primary embryo cells transfected with ras oncogenes are one or two orders of magnitude less likely to acquire long-term proliferative properties than those carrying a nuclear (e .g. c-myc, p53 , adenovirus EtA, etc) oncogene (172, 173) . These experiments show that ras oncogenes are highly inefficient in rescuing cells from senescence. Moreover, they indicate that induction of malignant transformation by ras oncogenes requires the establishment of a proliferative stage in the targeted cells. It is possible, however, that in vitro establishment may not be sufficient criteria to allow the phenotypic expression of ras oncogenes. Transformation of rat REF52 cells by these oncogenes requires complementation by adenovir uses EIA (176) . Therefore, in vitro transformation of fibroblastic cells by ras oncogenes may require additional changes, often associated with, but not necessary for continuous proliferation.
Evaluation of the neoplastic properties of ras oncogenes in cells other than cultured fibroblasts has been somewhat hampered by the limited cell types that can be efficiently transfected by these oncogenes. The use of retroviruses carrying ms oncogenes has somewhat circumvented this problem. ras containing retroviruses efficiently transform rodent cells of hematopoietic origin, induding those of erythroid, lymphoid, and myeloid lineages (I77-ISO) . In the case of erythroid cells, the H-ras containing Harvey-MSV can induce their malignant transformation without affecting their differentiation program as these cells retain their property to synthesize hemoglobin upon induction (177) . Infection of murine mast cells by this virus enhances growth properties of these cells, leading to the establishment of long-term cell lines (17S). However, these Harvey-MSV -transformed mast cells require the con tinuous presence of interleukin-3 (IL-3) for growth, indicating that ras oncogenes do not participate in the IL-3 signal transduction pathway (17S).
Transformation of myeloid cells results in the generation of both mature macrophage-like and immature myelomonocytic cell lines (179) . Both could differentiate either spontaneously in the case of the more mature cells, or by treatment with phorbol esters in the case of the myelomonocytic cells (179) . Finally, infection of mouse lymphoid cells with BALB and Harvey-MSVs yields transformed early progenitor cells as determined by the absence of markers specific for the B or T cells (180) ., Unlike in the case of erythroid and myeloid cells, these early progenitor lymphoid cells cannot be induced to differentiate into more mature lymphoid lineages (180) .
Neither cellular nor retroviral ras oncogenes have been able to induce stable transformation of normal human fibroblasts (181). However, transfec tion of normal human bronchial epithelial cells by a DNA clone of the Harvey-MSV ras oncogene has yielded colonies of transformed cells (182) . These cells are obtained at very low frequency and after careful and long-term culture. They exhibit all the characteristics of malignant cells, including a highly aneuploid karyotype, which suggests that multiple genetic changes have occurred during in vitro selection (182). Other authors have been able to transform human epidermal keratinocytes (183) , embryonic kidney cells (184) , and normal fibroblasts (185) by ras-containing retroviruses. However, transformation of these cells req uired prior acquisition of indefinite life-span by either infe ction with DNA tumor viruses such as ADI2-SV40 (183) and BK (184) or by treatment with 6 0 Co a-rays (185) .
ras oncogenes can also confer additional neoplastic properties to cell lines derived from human tumors. Infection of a human osteosarcoma cell line, HOS, with Kirsten-MSV not only induces drastic morphologic changes but confers on them the property of anchorage-independent growth and of produc ing tumors in nude mice (186) . Transfection of MCF-7 breast carcinoma cells with a DNA clone of Harvey-MSV causes loss of estrogen dependence for neoplastic growth (187) . However, bypassing estrogen dependence does not appear to be an intrinsic property of ras oncogenes since MCF-7 cells transfected with cellular H-ras-l oncogenes re main hormone dependent (S. Sukumar, personal communication). Thus, it is likely that ras oncogenes can only induce the loss of hormone dependence in MCF-7 cells when driven by powerful transcriptional enhancers such as retroviral L TRs. ras 
Oncogenes and Experimental Metastasis
The ability of ras oncogenes to induce metastatic phenotypes has been investigated. NIH3T3 and primary rat embryo cells transfected with ras oncogenes can form metastatic nodules in the lung when injected sub cutaneously in nude mice (173, (188) (189) (190) lines (191) or when these cells were injected intravenously (191, 192) . In the case of IOTI/2 mouse cells expression of the metastatic phenotype (as de termined by intravenous injection) correlates with the levels of expression of transfected H-ras-I oncogenes (I 92a). In a different system however, transfection of MT I CI 517 mouse mammary carcinoma cells with the same human H-ras-I oncogene only increased their capacity to metastasize when injected subcutaneously but not intravenously (193) . These results suggest that the primary effect of the H-ras-I oncogene may relate to their ability to escape the primary tumor site rather than to colonize new sites (193) .
Comparative studies using different mouse cell lines indicate that ras oncogenes will confer metastatic properties to NIH3T3 cells, but not C 127 cells (190) . These results are independent of the levels of expression of p2 1 ras proteins (190) . Thus, induction of the metastatic phenotype is not an intrinsic property of ras oncogenes . This concept is further supported by the similar incidence of ras oncogenes in primary and metastatic tumors (47) (48) (49) . ras 
Oncogenes and Terminal Diffe rentiation
In addition to their transforming properties, ra.\' oncogenes can also induce terminal di ffere ntiation of a rat pheochromocytoma cell line designated PC 12. PC 12 cells can differentiate into neuron-like cells if infected with ras containing retroviruses or microinjected with oncogenic, but not normal , p2 1 ras proteins (40--42) . Treatment of PC 12 cells with nerve growth factor (NGF) or cAMP has been shown previously to promote neurite outgrowth (194, 195) . Differentiation of PC I2 cells induced by ras oncogenes clearly proceeds by a mechanism independent of cAMP. However, ras oncogenes induce differentiation markers very similar to those induced by NGF. Moreover, both ras oncogenes and NGF have a lag of 15-24 hours and require RNA and protein synthesis to induce the neural differentiation of PC 12 cells (40-42). Thus, it is possible that ras oncogenes may participate in a signal transduction pathway commonly used by NGF. This hypothesis has been strengthened by a recent report showing that microinjection of PC 12 cells with antibodies (Y 13-259) against p2 1 ras proteins inhibits neurite formation induced by NGF but not by cAMP (196) .
At least one other oncogene, v-src, has been shown to promote neural differentiation in PC 12 cells (197) . The effect of v-src is highly reminiscent of the effect of ras oncogenes. Interestingly, linkage between src and ras oncogenes has been suggested by two independent lines of evidence. As described above, NlH3T3 cells transformed by v-src cannot enter the S phase when microinjected with anti-ras Y 13-259 antibodies (153). In the next section, I discuss the existence of flat revertants of Kirsten-MSV cells that can suppress the transforming phenotype induced by v-src (198 
Suppressor Genes
One of the advantages of studying ras genes in microorganisms is the possibility of identifying genes that can suppress the abnormal phenotypes induced by ras genes carrying mutations equivalent to those that activate mammalian ras oncogenes. The first of these suppressors (sup H) has been recently identified (198a). sup H is an allele of ste 16, a yeast mutant that does not produce functional a-factor, a mating pheromone. The carboxy terminus of the a-factor is Cys-Val-Ile-Ala-COOH, a sequence similar to the consensus carboxy terminus of ras proteins, Cys-A-A-X-COOH (see section on Mem brane Attachment) . Thus, it is likely that sup H (now designated RAM, for RAS protein and a-factor maturation function) represents a mutation in a gene coding for an enzyme responsible for the attachment of fatty acid to the carboxy terminal eys residue of the RAS2 Val19 protein (l98a).
In mammalian cells there is also genetic evidence for the existence of suppressors of ras oncogenes. Flat revertants of NIH3T3 cells transformed with Kirsten-MSV have been described (198, 199) . These revertants express high levels of biochemically active p2 1 protein, have rescuable transforming viruses, and cannot be retransformed by infection with Kirsten-MSV (198, 199) . These cells are not tumorigenic and exhibit a very low frequency of retransformation even after long periods of culture. Cell hybridization studies have shown that the revertant phenotype is dominant in hybrids between revertant cells and cells transformed by several ras oncogenes (198) . These results suggest that the revertant phenotype is not due to the absence of a cellular protein (e.g. a protein located downstream in the putative ras signal ing pathway). Recently, it has been possible to transmit this suppressor phenotype to other ras-transformed NIH3T3 cells by standard gene transfer technology (M. Noda, personal communication) .
Hybridization studies between these flat revertants of Kirsten-MSV NIH3T3 cells and cells transformed by other oncogenes indicate that the ras suppressor mutation can also suppress transformation induced by the v-fe s and v-src oncogenes but not by v-mos, v-fms, or v-sis (198) . These results are in good agreement (with the exception of those for v-fms) with those obtained by microinjection of anti-p21 monoclonal antibodies (153) . Although the evi dence is still mostly circumstantial , it is possible that ras, fe s, and src genes are part of the same or interconnected signaling pathways.
Additional experimental evidence supports the existence of ras suppressor genes. Syrian hamster tumors induced by cells transformed by cooperating ras and myc oncogenes exhibit the nonrandom loss of chromosome 15 (200) . Fusion of human tumor cell lines carrying ras oncogenes (e.g. HT-1 080 and EJ cells) with normal human fibroblasts yields nontumorigenic cells (201, 202) . Similarly, fusion of Chinese hamster cells transformed with ras oncogenes to nontransfonned Chinese hamster cells results in loss of tumorigenicity (203) . Most of the hybrids, generated by fusion bctween normal and tumorigenic cells, are morphologically transformed, indicating that the putative gene(s) involved in the suppression of tumorigenicity must be different from those responsible for the flat phenotype of the Kirsten-MSV revertants. Moreover, some human tumor cell lines containing ras oncogenes (e.g. T24 bladder carcinoma cells) are "nontumorigenic" in nude mouse assays (204, 205) . Thus, it is possible that those genes involved in the suppression of tumorigenicity of ras-transformed cells may not exert their inhibitory action by direct interaction with ras oncogenes.
ras ONCOGENES IN ANIMAL TUMORS
ras oncogenes have been implicated in the development of a variety of tumors. They have been found in four strains of acute transforming retrovir uses of rodents (3) (4) (5) (6) and are occasionally activated in tumors induced by retroviruses that do not carry oncogenes (20; J. lhle, personal communica tion). ras oncogenes, however, have been more frequently identified in tumors of nonviral etiology. In particular, animal tumors induced by chemical or physical carcinogens have been an abundant source of this class of oncogenes (150) . Moreover, ras oncogenes are present in about 10% of the most common forms of human neoplasia, thus making them the most fre quently identified oncogene family in human cancer (47) (48) (49) .
As documented in the previous section, the transforming properties of ras oncogenes have been extensively documented in in vitro cell culture systems. However, cancer is a multistage disease that probably results from accumula tion of independent genetic and epigenetic errors . The progressive generation of aneuploidy during tumor development suggests that most of the aberrations present in tumor cells may occur after malignancy has been irreversibly established. Therefore , the basic question posed by the frequent identification of ras oncogenes in spontaneous tumors such as those of humans is whether ras oncogenes participate in the induction of neoplastic development or are a consequence of it. Some experimental evidence suggests that ras oncogenes can, in fact, become activated after cells have acquired neoplastic properties (206) (207) (208) . However, recent results obtained in animal model systems indi cate that ras oncogenes are more likely to participate in the initiation of tumor development. These findings will be reviewed in this section.
Carcinogen-Induced Tumors
ras oncogenes have been found to be reproducibly activated in a variety of carcinogen-induced animal model tumor systems (Table I) . In rats, induction of mammary carcinomas by a single dose of nitroso-methylurea (NMU) during puberty leads to the activation of H-ras-I oncogenes in 86% of the tUmors (12, 209) . Substitution of this carcinogen by dimethyl benz(a)anthracene (DMBA) also results in the malignant activation of the H-ras-l locus although in only one fourth of the tumors (209) . Activation of the K-ras-2 locus has been observed in 40% of kidney mesenchymal tumors induced by a single dose of methyl(methoxymethyl)nitrosamine (DMN) (210) and in 74% of lung tumors (adenocarcinomas and squamous cell carcinomas) by chronic exposure to tetranitromethane (TNM) (1. Stower, M. W. An derson , personal communication).
In mice (Table 1) , H-ras-l oncogenes have been fo und to be reproducibly activated in 90% of skin papillomas and carcinomas of Sencar mice initiated by DMBA or dibenz(c,h)acridine (DBACR) treatment and followed by pro motion with TPA (21 1-213) . Similarly, H-ras-l oncogenes have been found in each of 4 mammary tumors arising from hyperplastic alveolar nodules implanted in mice treated with DMBA (2 14). Exposure of AKRxRF hybrid mice to X-rays or to repeated NMU treatment leads to the induction of lymphomas, most of which (over 60%) contain activated K-ras-2 or N-ras . The frequent and reproducib:te activation of ras oncogenes in these animal tumors strongly supports the concept that ras oncogenes play a causative role in neoplastic development (Table I) . ras oncogenes have also been randomly « 10% incidence) identified in certain animal model systems such as rat fibrosarcomas induced by either 1,6-or 1,8-dinitropyrene (217a, M. Nagao, personal communication) or liver carcinomas. induced by methyl(acetoxymethyl)nitrosamine (DMN-OAc) (J. Rice, personal communication). Finally, ras oncogenes have been idcntified in certain rodent cell lines transformed by in vitro exposure to chemical carcinogens. Whereas the K-ras-2 oncogene was found in mouse ceIls treated with 3-methyl-cholanthrene (MeA) (2 18), N-ras was found to be activated in four tumorigcnic guinea pig cell lines initiated by nitroso compounds and polycyclic hydrocarbons (2 19; 1. Doniger, personal communication). ras 
Genes as Ta rgets of Carcinogens
It is generally accepted that most carcinogens are mutagens. A significant number of chemical carcinogens are known to form adducts with DNA bases (reviewed in 220). Whereas some of these adducts are highly mutagenic due to their miscoding properties (221, 222) , others can lead to mutations due to the generation of apurinic sites or because of the limited fidelity of repair polymerast:s (reviewed in 223). Whereas most of these mutations will have no consequence to the host, a small number of them can trigger neoplastic development. Identification of these critical mutations has eluded scientists for many years .
The reproducible activation of ras oncogenes in carcinogen-induced tumors has made it possible to correlate their activating mutations with the known mutagenic effects of certain carcinogens ( Table 2) . Each of the H-ras-l oncogenes present in rat mammary carcinomas induced by NMU but not DMBA became activated by G � A transitions are the most common mutations induced by NMU (221, 222) . These mutations result from the miscoding properties of 0 6 -methylguanosine, one of the adducts generated by the methylating activity of NMU. In contrast, DMBA forms large adducts with adenine and guanine residues whose repair very seldom leads to the generation of G -A substitutions (220). These findings have led to the proposal that NMU is directly responsible for the malignant activation of H-ras-l oncogenes in these mammary tumors (209) .
Although the H-ras-l locus can be activated by G -A substitutions in either of the two guanine residues present in the 12th codon (GGA) , only those affecting the middle position (G 3 5 ) have been observed in NMU induced mammary carcinomas (209) . Such a strong positional effect adds further support to the concept that NMU is directly involved in the generation of these mutations. A possible explanation for the reproducible occurrence of G 3 5 _ A 3 5 transitions in these tumors has recently been obtained. Analysis of the rate of repair of 06-methylguanosine residues in the ampicillanase gene of a bacteriophage fl/pBR322 plasmid chimera has revealed a DNA consensus sequence around * unrepaired G * residues (224) . This sequence, GCTGGTCGCCAGGAGG, where G is the unrepaired 0 6 MeG residue, is 75% homologous (12 out of 16 residues) to the rat H-ras-l sequence around the critical 12th codon (underlined in the consensus sequence) . The probabil ity of a random match with this stringency is 0.0017. Moreover, no other sequence in the entire H -ras-l locus exhibits a similar match with this consensus sequence (224). Therefore , it is possible that NMU may induce mammary carcinomas in rats by interacting with a DNA sequence within a critical proto-oncogene domain that cannot be efficiently repaired.
The concept that ras oncogenes can be the targets of chemical carcinogens has been further supported by recent experimental evidence obtained with other animal tumor model systems ( Table 2) . Induction of skin carcinomas in mice by DMBA and phorbol esters involves the specific activation of H-ras-l oncogenes by A -T transitions in the second base of codon 61 (212, 213) . However, this mutation has not been seen when the initiating carcinogen , These findings , taken together, indicate that ras oncogenes can be directly activated by the mutagenic properties of the initiating carcinogens.
Multistep Carcinogenesis
Activation of ras oncogenes by the initiating carcinogens in tumors induced by a single: carcinogenic insult implies that these oncogenes must participate in the initiation of neoplastic development (209, 212, 217) . This concept is supported by the identification of transforming H -ras-l genes in the majority of skin papillomas induced by topical application of DMBA or DBACR followed by treatment with tumor promoters (213, 228) . Most of these papillomas will regress spontaneously and only a few of them will develop as malignant carcinomas . These results provide independent biological evidence that ras genes can be activated during the early stages of tumor development (213, 228) . Activation of ras oncogenes is not sufficient to trigger tumorigenesis. Emerging evidence indicates that they must cooperate with secondary genetic events and/or with specific developmental programs in order to elicit neoplas tic development. For instance, it has been shown that the active stage of proliferation of the developing mammary gland at the time of the carcinogen insult plays a fundamental role in tumor development (reviewed in 229). Recent results, however, indicate that activation of ras oncogenes does not have to be concomitant with mammary gland development (S. Sukumar, personal communication). Treatment of newborn rats with a single dose of NMU leads to the development of mammary carcinomas 2-3 months after the animals have reached sexual development. Most of these tumors carry H-ras I oncogenes, each activated by the G ----'> A transition diagnostic of NMU induced mutagenesis. Treatment of these animals with antiestrogen drugs followed by ovariectomy eliminates the occurrence of mammary carcinomas (S . Sukumar, personal communication). These observations suggest that whereas H-ras-I oncogenes might become activated early in life , manifesta tion of their malignant properties requires the hormone-induced proliferation and/or differentiation that takes place in the mammary gland during sexual maturation .
A similar situation may occur in the skin carcinogenesis model of mice. Initiated cells are known to remain dormant in the skin of DMBA-treated mice for long periods of time until they are treated with tumor promoters (230) . Considering that most of the papillomas and carcinomas generated in this model system contain H-ras-I oncogenes (2 1 1-213, 228), it is likely that these initiated cells already carry activated raS oncogenes. Direct support for this hypothesis has been recently obtained (23 1). Infection of mouse epidermal skin cells with Harvey-MSV results in the generation of initiated cells that do not express discernible neoplastic properties unless they are treated with TPA. These re sults indicate that in this model system ras oncogenes also require cooperation with cellular proliferation to allow expres sion of their neoplastic properties.
Induction of skin carcinomas by Harvey-MSV has provided direct ex perimental evidence for the existence of secondary genetic events in ras induced tumors (23 1). Whereas Harvey MSV-induced papillomas appear to be polyclonal, the malignant carcinomas are clonal in origin. Papillomas are known to regress to small hyperkeriotie lesions before a few of them begin their invasive growth characteristic of skin carcinomas. Therefore , a second genetic event distinct and independent from ras oncogene activation is re quired for development of skin carcinomas (23 1). Recently, it has been shown that skin grafts of cultured keratinocytes infected with Harvey-MSV lead to the generation of papillomas but not carcinomas (23 1 a) , thus adding further evidence to the concept that ras oncogenes are not sufficient for the develop ment of the full malignant phenotype in, at least, this model system. Similar conclusions have been obtained by independent studies utilizing transgenic mice. Mice carrying in their germ line H-ras oncogenes linked to the promoter region of the mouse whey acidic protein (W AP) gene (N. Hynes, B. Groner, personal communication) or to the LTR of the mouse mammary tumor virus (MMTV) (P. Leder, personal communication). These animals develop single mammary tumors after a re latively long latent period, suggesting that a secondary event is necessary for tumor development. Mating transgenic mice carrying MMTV -ras chimeras with those containing MMTVAnnu. Rev The requirement of a second genetic event may not be necessary if ras oncogenes are activated during the early stages of development. Transgenic mice carrying ras oncogenes under the transcriptional control of the elastase promoter die of pancreatic tumors a few days after birth (R. Palmiter, personal communication). In mice, the pancreas evolves from the gut at day II of gestation . At day 14 to 15, elastase begins to bc expressed in the acimer cells of the pancreas and by day 16 tumors can already be detected . In contrast, the pancreas of transgenic mice carrying the normal ras proto-onco gene linked to the elastase promoter developed normally and the mice sur vived up to one year of age (R. Palmiter, personal communication). These results dramatically illustrate that under certain circumstances expression of a single ras oncogene is sufficient to induce tumor development.
Retrovirus-Induced Tumors
To date , fo ur ras-containing retroviruses have been identified. They include Harvey-MSV isolated by inoculation of rats with Moloney murine leukemia virus (MuL V) followed by injection of the rat-passaged virus into newborn BALB/c mice (I), Kirsten-MSV derived from rats inoculated with cell-free filtrates from thymic lymphomas of old C3H mice (2), BALB-MSV isolated from an hemangiosarcoma of a BALB/c mouse induced by transmission of a cell-free extract of blood from a spontaneous chloroleukemia of an 18-month old BALB/c mouse (233, 234) , and Rasheed-MSV generated by in vitro . cocultivation of a spontaneously transformed rat cell line (235) . These viruses primarily cause erythroleukemias and fibrosarcomas when injected into new born rodents. However, the pathogenic spectrum of these viruses can be altered by manipulations involving changes in dose, route of administration, strains, age of infected animals, etc. These studies have been extensively reviewed in the past (175, 236) and will not be considered here any further.
Introduction of the human H-ras-I oncogene isolated from the T24/EJ bladder carcinoma cell line into appropriate vectors has also yielded transforming retroviruses. These viruses can also induce erythroleukemias and sarcomas when injected into newborn miee (236a). These experiments illustrate th� wide malignant spectrum of human ras oncogenes. However, they should be interpreted with caution as the levels of expression of these human ras oncogenes are much higher in retrovirus-infected cells that they would normally be in human tumors.
Construction of similar retroviruses carrying the normal human H-ras-I proto-oncogene did not yield transforming viruses (236a). These results are somewhat surprising considering the in vitro transforming properties of LTR ras proto-oncogene chimeras (3, 159) . In related experiments, the miscoding mutations of codons 12 and 59 of the H-ras oncogene present in Harvey-MSV have been eliminated (73) . The resulting Gly 12 /Ala 59 Harvey-MSV mutant virus exhibits decreased transforming properties, although it retains the capac ity to transform NIH3T3 cells and rat embryo cells (73) . Other authors have reported that whereas transcriptionally enhanced ras proto-oncogenes cannot transform primary rat embryo cultures, they can confer long-term pro liferative properties to the transfected cells (171) . The reasons for these discrepancies probably lie in the different constructs and assay conditions used in these experiments. Replication-competent retroviruses that do possess oncogene sequences may also exert their neoplastic properties by transcriptional activation of cellular ras genes. Induction of a chicken nephroblastoma by a myeloblasto sis-associated retrovirus resulted in elevated levels (25-fold) of a novel H-ras transcript that contained retroviral LTR U5 sequences (20) . Viral integration did not occur adjacent to the H-ras locus but probably next to a distant splicing donor site. Sequence analysis of a DNA clone complementary to the hybrid LTR U5-H-ras transcript showed no mutations in any of the critical ras codons (20) . Thus, it is likely that transcriptional activation of the normal chicken H-ras locus contributed to the development of this tumor.
A related event may have accounted for the highly elevated (30-fold) expression of p2 1 ras proteins in a myeloid cell line (4 1 68) derived from a mouse bone-marrow culture infected with the Friend retrovirus complex (237, 238) . In this case, a 3.5 kbp segment of the Friend helper virus was inserted within the first intron of the mouse K-ras-2 locus (2 1). As a result, K-ras-2 transcription was initiated at a new site (presumably within the retroviral LTR) that excluded the first K-ras-2 noncoding exon located upstream from the viral integration site (2 1). The original 4168 cells were nontumorigenic (237, 238) . However, these cells have now become malignant, presumably as a consequence of continuous passage in vitro (2 1). These observations sug gest that transcriptional activation of the K-ras-2 locus in this mouse hematopoietic cell line may have contributed, but was not sufficient to induce tumorigenic properties in these cells. Similar findings have been recently obtained in DA-2 cells, a cell line derived from a Moloney murine leukemia virus (MLV)-induced tumor. In these cells, Moloney-ML V sequences be came integrated 5' of the first coding exon of the H-ras-I locus (J . Ihle, personal communication). This genomic rearrangement is likely to be responsible for the high levels of expression of p2 1 ras proteins observed in DA-2 cells and it is presumed to have contributed to tumor development. initial aggressive growth fo llowed by spontaneous regression. These findings resemble those observed in the mouse skin model tumor system (see previous section) in which H-ras-I oncogenes were shown to participate in the early stages of tumor development. So far, transforming ras genes are the oncogenes most frequently identified in human cancer. Their overall incidence is estimated to be around 1 0--15%. This figure is likely to be lower in certain malignancies such as breast carcinoma, while it may be higher in other tumors such as acute myelogenous leukemia (89). The actual incidence of ras oncogenes in human tumors is difficult to assess. Available information has been obtained from transfection assays, which are somewhat insensitive, particularly in detecting large oncogenes such as K-ras-2. Moreover, many scientists do not conduct paral lel experiments to test the sensitivity of their transfection assays and to control for the intactness of the donor DNA. This is of particular importance in laboratories that lack direct access to reliable tumor material. Finally, some authors only report those tumors or tumor cell lines in which they have obtained positive results. Recent studies utilizing the RNA : RNA hybrid mismatch technology (see next section) have shown the presence of K-ras-2 oncogenes carrying codon 12 mutations in 22 of 55 colon carcinomas (M.
Perucho, personal communication). Considering that mutations at codon 61
of K-ras-2 oncogenes have not yet been analyzed and that N-ras oncogenes have also been fo und in colon carcinomas (49), the overall incidence of ras oncogenes in this common type of human cancer may have been un derestimate:d. In any case, available information to date indicates that (a) ras oncogenes are present in a significant percentage (varying from 5 to 40%) of most human tumors; (b) they are not associated with specific types of neo-plasia; and (c) their activation does not correlate with the histo-pathological properties of the tumor.
The involvement of ras genes in human cancer is not limited to their activation by point mutations. It is likely that expression of a bnormally high levels of normal ras products may also contribute to malignancy. This could be achieved by perturbation of their regulatory sequences (20, 21) or by gene amplification. In human tumors, there is no evidence for transcriptional activation of ras proto-oncogenes by mutations affecting their regulatory elements. In contrast, significant amplification ( :;;;, 10 fo ld) of ras genes has been observed in a variety of human tumors (160, (239) (240) (241) (242) . However, the overall incidence of ras gene amplification in human neoplasia is estimated to be not higher than 1% (160, 240) .
Loss of the normal allele in cclls carrying ras oncogenes has been observed with relative frequency in tumor cell lines, but only rarely in tumor biopsies (243) . Interestingly, loss of ras alleles also occurs in tumors that do not carry ras oncogenes (240, 244, 245) . Whether these deletions play any role in the pathogenesis of human cancer remains to be determined.
Expression Studies
Expression of ras genes is often increased in tumors relative to normal tissues. Careful quantitative analysis has indicated that the levels of ras transcripts in about 50% of human tumors are 2-to IO-fold higher than in control tissue (246-248). Similar results have been obtained by immunoblot analysis of p2 1 ras expression in a variety of primary carcinomas (249-25 1) . Surprisingly, metastatic tissues derived from primary colon carcinomas consistently exhib ited low levels of p2 1 ras proteins (249). The expression of ras genes in human tumors has also been studied by immunohistochemical techniques. Immunocytochemistry has the advantage of allowing the evaluation of ras gene expression in individual cells. These studies have utilized two mono clonal antibodies, Y 13-259 (120) and RAP-5 (252), neither of which dis criminates between the different p21 ras proteins or between their normal and activated forms. Unfortunately, no clear picture has emerged from these studies. Some authors have consistently identified increased levels of im munoreactivity in malignant cells of mammary (252) , colon (253) , bladder (254) , and prostate (255) carcinomas as compared to those of corresponding benign tumors, dysplastic lesions, or normal epithelium. Other authors, however, have not been able to detect any significant differences between normal and malignant tissues (256) (257) (258) . Moreover, two independent labora tories have reported that the RAP-5 monoclonal antibody may recognize a cytoplasmic cellular component distinct from p2 1 (258, 258a) . In this regard, it is worthwhile to note that a monoclonal antibody that specifically recog nizes Val 12 p2 1 ras proteins by immunoblotting or even by immunoAnnu. Rev 159, 159a, 160) . However, in these cases a 30-to 100-fold increase in the levels of both mRNA and p2 1 ras protein expression has been consistently observed. On the other hand, increases in ras transcripts of up to eight-fold can be associated with normal proliferative processes such as regenerating rat liver (156) . Therefore , there is not sufficient experimental basis to implicate moderate variation of ras proto-oncogene expression in the neoplastic development of human tumors.
Predisposition to Cancer
Extensive genetic evidence suggests the existence of genes responsible for the predisposition of certain individuals to cancer. ras oncogenes may not belong to this class of genes . First of all, ras oncogenes become activated in somatic rather than in germ line cells (89, 243, 260, 261) . Second, normal cells of patients with high cancer risk syndromes do not contain ras oncogenes (262). However, a recent population study on the frequency of H-ras-1 alleles in normal individuals versus cancer patients has revealed a statistically signifi cant correlation between the latter and certain unusual H-ras-1 alleles (244) .
The human H-ras-1 Iocus contains a region of around 800 bp of tandemly repeated sequences located 1000 bp downstream from its polyadenylation signal (58) . Genetic variability within this stretch of repeated sequences generates a variety of restriction fragment length polymorphisms (RFLP) . Up to 20 polymorphic H-ras-l alleles have been identified, of which only four are commonly fo und in the human population (244) . Of a total of 230 samples of white blood cells of normal donors, only 9 (3.9%) exhibited any of the 16 rare alleles. In contrast, of 298 samples of either normal or tumor tissue from cancer patients, 32 (10.7%) contained rare alleles. No significant difference was seen between normal and tumor samples of cancer patients , indicating that the increased frequency of rare alleles in these patients is an inherited property alll d not a consequence of somatic events associated with tumor development (244) . All tumor types, including myelodysplastic lesions, were associated with rare H-ras-l alleles, suggesting that these RFLPs are in dicative of genetic predisposition to most, if not all, forms of cancer. Differ ent results have been obtained in an independent study investigating the frequency of rare H-ras-l alleles in lung cancer (245) . In this study, 132 patients were examined, 66 with small cell lung carcinomas (SCLC) and 66 with non-SCLC. Rare H-ras-l allelic patterns were found in patients with non-SCLC but not in those with SCLC (245). These observations suggest that large numbers of cancer patients must be examined to fully assess the incidence of rare H-ras-I alleles in specific types of malignancies. The need for such studies has been further indicated by recent reports contesting the possible linkage between rare H-ras-I RFLP and the development of myelodysplasia (263) and melanoma (263a).
It is not clear how these rare H-ras-I alleles may predispose to cancer. It has been speculated that the rare alleles representing specific arrays of tan dem-repeats may be in linkage disequilibrium with missense mutations in the H -ras-l coding sequences that may confer weakly oncogenic properties to this locus (244) . Recently, it has been shown that these polymorphic repeated sequences have enhancer activity in in vitro CAT assays (263b; S. Ishii, personal communication). Thus, it is possible that a somewhat altered regula tion over long periods of time of the H-ras-I gene or of a putative neighboring locus may predispose certain cells to neoplastic growth. However, ex perimental evidence to support any of these hypotheses has, as yet, to be obtained.
New Diagnostic Methods
So far, identification of ras oncogenes in human tumors has relied on tedious and insensitive transfection assays. It is evident that any attempt to utilize information on activation of ras oncogenes in clinical studies will require the development of faster and more sensitive diagnostic methods. The first step in this direction has involved the use of oligonucleotides of defined sequence to identify single point mutations in genomic DNA. Hybrids between oligonuc leotides that form a perfect match with genomic sequences are more stable than those that exhibit a single mismatch (264) . Oligonucleotides correspond ing to sequences surrounding the critical 12th and 61 st codons of ras genes have been successfully used to identify the presence of ras oncogenes in certain human neoplasias (89, 265) . In spite of the significant advantages of oligonucleotide probing over current gene transfer assays, this technique is still somewhat cumbersome. ras genes can theoretically be activated by almost 100 different base substitutions, of which over 30 have already been identified in naturally occurring tumors (49) . This heterogeneity can be partially overcome by using oligonucleotide mixtures containing each of the three possible substitutions at a given residue (89, 265) . Nevertheless, the significant number of oligonucleotide probes required to identify each possi ble ras oncogene limits the general applicability of this technique.
Several new methods capable of identifying single point mutations over (267 , 268) . Hybridization of tumor DNA or RNA samples with these probf:s, followed by incubation with RNAse A, cleaves the labeled RNA probes into fragments of defined sizes that can be easily resolved by polyacrylamide gel electrophoresis. These techniques can identify most base substitutions (267, 268) . Moreover, the RNA :RNA hybrid method provides useful information regarding the levels of expression of ras oncogenes in these tumors. In addition, the relative expression of both normal and transforming alleles can be analyzed (267) . Recently, a new method involving the primer-mediated enzymatic amplification of specific genomic sequences has been df:veloped (269) . This process, which can easily be automated (K. Mullis, personal communication) , should make possible the routine use of oligonucleotide probes to identify ras oncogenes in clinical laboratories.
In spite of these technological improvements , the use ,of riucleic acid hybridization techniques to identify human ras oncogenes would always require the use of six different probes (specific for the first and second exons of each of the three ras loci) and enough tissue to obtain sufficient amounts of RNA or DNA . In theory, a more practical approach would be to generate monoclonal antibodies capable of discriminating between the putative "ac tive" and "inactive" conformation of p2 1 ras proteins (see Figure 2) . Un fortunately, antibodies elicited against peptides containing the missense muta tions characteristic of ras oncogenes only identify those p21 ras proteins carr ying the: amino acid substitutions present in the immunizing peptide (102, 259, 270) . On the other hand, antibodies elicited against bacteria-synthesized p21 ras proteins recognize the normal and oncogenic forms with equal efficiency (our unpublished observations) , X-ray crystallographic analysis of p21 molecules should help in identifying putative domains that may elicit such diagnostic antibodies, A potential caveat in using monoclonal antibodies to identify the products of ras oncogenes in human tissue sections is the potential lack of specificity (see previous section). Monoclonal antibodies capable of recognizing oncogenic ras proteins carrying Vall2 substitutions by immunoblotting an alysis have been shown to be highly specific in immunoperoxidase staining of human carcinoma cell lines in culture (259) . However, when this antibody was used to analyze formalin-fixed tumor biopsies, a significant number gave false positive results (259) . Therefore , further work will be required to work out the technical challenges posed by the diagnostic identification of ras oncogenes in human tumor biopsies.
Future A venues
In spite of the extensive documentation on the malignant properties of ras oncogenes, their presence in human tumors cannot be considered as sufficient evidence of a causative role in the pathogenesis of human cancer. Results obtained with carcinogen-induced tumors and transgenic mice have indicated that ras oncogenes can participate in the initiation of carcinogenesis. Howev er, these observations do not preclude the possibility that ras oncogenes may also be generated in cells that have already acquired neoplastic properties. To evaluate the involvement of ras oncogenes in human cancer it is necessary to determine what percentage of ras oncogenes plays a primordial role in tumor development and what percentage becomes activated as a consequence of it. Unfortunately, this question cannot be easily addressed as in human carcino genesis it is virtually impossible to backtrack to the early events that led to neoplastic development.
Future progress on the involvement of ras oncogenes in human cancer depends on results derived from two independent avenues of research. First, we must continue ongoing efforts aimed at unveiling the molecular and biochemical mechanisms by which ras oncogenes disrupt the normal pro liferative programs. Second, we must develop fast and reliable diagnostic methods to allow the routine identification of ras oncogenes in human biop sies. This information, once applied to a large number of tumors, may reveal hidden connections between the activation of these oncogenes and the etiolo gy and/or pathology of human cancer.
It is evident that the molecular pathways that lead to carcinogenesis may not parallel the histo-pathological criteria that have served to develop current cancer treatment programs. We can only hope that understanding the mech anisms by which oncogenes participate in neoplasia may provide a more rational approach to cancer therapy. The presence of ras oncogenes in at least 10% of human cancers certainly justifies the intense interest dedicated to this gene family during the last few years .
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